Fluid phase biomarkers in multiple sclerosis.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
10
6
2022
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is highly heterogenic disorder with respect to clinical course, diagnosis, and treatment response. There is an urgent need to search for simply and reliable fluid body biomarker which would assist the diagnosis and prediction of clinical and treatment prognosis. 'Traditional' MS biomarkers, with exception of cerebrospinal fluid oligoclonal bands, still are having limited clinical value. Therefore, there is growing interest in novel molecules and ingredients. The most robust results have been generated with regard to cerebrospinal fluid and serum levels of neurofilament light chains (NfL). However, there are still some limitations related to specificity of NfL which delays its use in everyday practice. We present a new approach to search for biomarkers involving extracellular RNA, particularly microRNA (miRNA), and small extracellular vesicles. MiRNA represents an important molecular mechanism influencing gene expression, including those involved in MS pathogenesis and extracellular vesicles transfer multiple cargo, including myelin molecules from parental cells of central nervous system to the long-distance targets. MiRNAs which control gene expression in cells involved in autoimmune processes in MS as well as extracellular vesicles transferring myelin content might generate a new promising categories of biomarkers of MS.
Identifiants
pubmed: 35674070
doi: 10.1097/WCO.0000000000001058
pii: 00019052-202206000-00006
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-292Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Deisenhammer F, Zetterberg H, Fitzner B, et al. The cerebrospinal fluid in multiple sclerosis. Front Immunol 2019; 10:1–10.
Pryce G, Baker D. Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter ? Mult Scler Relat Disord 2018; 25:131–137.
Matute-Blanch C, Villar LM, Alvarez-Cermerio JC, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain 2018; 141:1085–1093.
Tintore M, Rovira A, Rio J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138:1863–1874.
Villar L, Garcia-Barragain N, Roldan E, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115:187–194.
Arneth B, Kraus J. Laboratory biomarkers of multiple sclerosis (MS). Clin Biochem 2021; 99:1–8.
Giedraitiene N, Drukteiniene E, Kizlaitiene R, et al. Cognitive decline in multiple sclerosis is related to the progression of retinal atrophy and presence of oligoclonal bands: a 5-year follow-up study. Front Neurol 2021; 12:678735.
Link H. The value of cerebrospinal fluid immunoglobulin analysis in clincial neurology. Riv Patol Nerv Ment 1976; 97:323–340.
Klein A, Selter RC, Hapfelmeier A, et al. CSF parameters associated with early MRI activity in patients with MS. Neurol Neuroimmunol Neuroinflamm 2019; 6:e573.
Goldsmith JF, Herskovits AZ. Cerebrospinal fluid testing for multiple sclerosis. Clin Lab Med 2020.
Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59:555–559.
Pfuhl C, Grittner U, Gieß RM, et al. Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. Neurology 2019; 93:e1439–e1451.
Vecchio D, Bellomo G, Serino R, et al. Intrathecal kappa free light chains as markers for multiple sclerosis. Sci Rep 2020; 10:20329.
Rosenstein I, Rasch S, Axelsson M, et al. Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: a real-world investigation. J Neurochem 2021; 159:618–628.
Berek K, Bsteh G, Auer M, et al. Kappa-free light chains in CSF predict early multiple sclerosis disease activity. Neurol Neuroimmunol Neuroinflamm 2021; 8:e1005.
Presslauer S, Milosavljevic D, Brucke T, et al. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008; 255:1508–1514.
Cubas-Núñez L, Gil-Perotín S, Castillo-Villalba J, et al. Potential role of CHI3L1+ astrocytes in progression in MS. Neurol Neuroimmunol Neuroinflamm 2021; 8:e972.
Sellebjerg F, Royen L, Soelberg Sørensen P, et al. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler 2019; 25:1444–1451.
Burman J, Raininko R, Blennow K, et al. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol 2016; 292:52–57.
Comabella M, Clarke MA, Schaedelin S, et al. CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Mult Scler 2021; 28:71–81.
Oldoni E, Smets I, Mallants K, et al. CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity. Ann Neurol 2020; 87:633–645.
Holloman JP, Axtell RC, Monson NL, Wu GF. The role of B cells in primary progressive multiple sclerosis. Front Neurol 2021; 12:680581.
Ferraro D, Galli V, Vitetta F, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. J Neuroimmunol 2015; 283:64–69.
Sun M, Liu N, Xie Q, et al. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: a systematic review and meta-analysis. Mult Scler Relat Disord 2021; 51:102870.
Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021; 20:762–772.
Greene DN, Schmidt RL, Wilson AR, et al. Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study. Am J Clin Pathol 2012; 138:262–272.
Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233:183–198.
Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 2017; 9:a018309.
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14:577–589.
Thebault S, Bose G, Booth R, Freedman MS. Serum neurofilament light in MS: the first true blood-based biomarker? Mult Scler 2021; 40:369–377.
Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011; 76:1206–1213.
Disanto G, Barro C, Benkert P, et al. Swiss multiple sclerosis cohort study group. serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81:857–870.
Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016; 54:1655–1661.
Bjornevik K, Munger KL, Cortese M, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol 2020; 77:58–64.
Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain 2018; 141:1085–1093.
Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2016; 87:126–129.
Bittner S, Steffen F, Uphaus T, et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine 2020; 56:102807.
Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 2008; 14:59–66.
Novakova L, Zetterberg H, Sundström P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 2017; 89:2230–2237.
Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018; 141:2382–2391.
Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019; 92:e1007–e1015.
Bridel C, Leurs CE, van Lierop ZYGJ, et al. Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis. Neurology 2021; 97:e1898–e1905.
Thebault S, Booth RA, Rush CA, et al. Serum neurofilament light chain measurement in MS: hurdles to clinical translation. Front Neurosci 2021; 15:654942.
Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of exosome composition. Cell 2019; 177:428–445.e18.
Yáñez-Mó M, Siljander PR-M, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015; 4:27066.
Scolding NJ, Morgan BP, Houston WA, et al. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 1989; 339:620–622.
Verderio C, Muzio L, Turola E, et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol 2012; 72:610–624.
Selmaj I, Cichalewska M, Namiecinska M, et al. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann Neurol 2017; 81:703–717.
Galazka G, Mycko MP, Selmaj I, et al. Multiple sclerosis: Serum-derived exosomes express myelin proteins. Mult Scler 2017; 24:449–458.
Sáenz-Cuesta M, Irizar H, Castillo-Triviño T, et al. Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. Biomark Med 2014; 8:653–661.
Muñoz-Culla M, Irizar H, Sáenz-Cuesta M, et al. SncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent. Sci Rep 2016; 6:20126.
Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018; 7:1–43.
D’Anca M, Fenoglio C, Buccellato FR, et al. Extracellular vesicles in multiple sclerosis: role in the pathogenesis and potential usefulness as biomarkers and therapeutic tools. Cells 2021; 10:1733.
Gutiérrez-Fernández M, Cuesta F, de la Tallón A, et al. Potential roles of extracellular vesicles as biomarkers and a novel treatment approach in multiple sclerosis. Int J Mol Sci 2021; 22:9011.
Marostica G, Gelibter S, Gironi M, et al. Extracellular vesicles in neuroinflammation. Front Cell Dev Biol 2021; 8:623039.
Manu MS, Hohjoh H, Yamamura T. Extracellular vesicles as pro- and anti-inflammatory mediators, biomarkers and potential therapeutic agents in multiple sclerosis. Aging Dis 2021; 12:1451.
Groen K, Maltby VE, Scott RJ, et al. Concentrations of plasma-borne extracellular particles differ between multiple sclerosis disease courses and compared to healthy controls. Mult Scler Relat Dis 2020; 45:102446.
Moyano AL, Ghiani CA, Li G, et al. Sulfatides in extracellular vesicles isolated from plasma of multiple sclerosis patients. J Neurosci Res 2016; 94:1579–1587.
Gelibter S, Pisa M, Croese T, et al. Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis. Ann Neurol 2021; 90:253–265.
Della Costa G, Croese T, Pisa M, et al. CSF extracellular vesicles and risk of disease activity after a first demyelinating event. Mult Scler J 2020; 27:1606–1610.
Bhargava P, Nogueras-Ortiz C, Kim S, et al. Synaptic and complement markers in extracellular vesicles in multiple sclerosis. Mult Scler J 2020; 27:509–518.
Costa GD, Finardi A, Garzetti L, et al. Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. Neurol Sci 2018; 39:373–376.
Amoruso A, Blonda M, D’Arrigo G, et al. Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients. J Neuroimmunol 2018; 323:43–48.
Sáenz-Cuesta M, Alberro A, Muñoz-Culla M, et al. The first dose of fingolimod affects circulating extracellular vesicles in multiple sclerosis patients. Int J Mol Sci 2018; 19:2448.
Murillo OD, Thistlethwaite W, Rozowsky J, et al. exRNA atlas analysis reveals distinct extracellular RNA cargo types and their carriers present across human biofluids. Cell 2019; 177:463–477.e15.
Selmaj I, Mycko MP, Raine CS, Selmaj KW. The role of exosomes in CNS inflammation and their involvement in multiple sclerosis. J Neuroimmunol 2017; 306:1–10.
Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108:5003–5008.
Nechooshtan G, Yunusov D, Chang K, Gingeras TR. Processing by RNase 1 forms tRNA halves and distinct Y RNA fragments in the extracellular environment. Nucleic Acids Res 2020; 48:8035–8049.
Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009; 136:26–36.
Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating noncoding RNAs – an update. Nat Rev Clin Oncol 2018; 15:541–563.
Mycko MP, Baranzini SE. microRNA and exosome profiling in multiple sclerosis. Mult Scler 2020; 26:599–604.
Regev K, Healy BC, Paul A, et al. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm 2018; 5:e491.
Hemond CC, Healy BC, Tauhid S, et al. MRI phenotypes in MS: longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm 2019; 6:e530.
Piket E, Zheleznyakova GY, Kular L, Jagodic M. Small noncoding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: a comprehensive overview. J Autoimmun 2019; 101:17–25.
Zhou Z, Xiong H, Xie F, et al. Meta-analytic review of the value of miRNA for multiple sclerosis diagnosis. Front Neurol 2020; 11:132.
Zailaie SA, Siddiqui JJ, Al Saadi RM, et al. Serum based miRNA as a diagnostic biomarker for multiple sclerosis: a systematic review and meta-analysis. Immunol Invest 2021; 1–16. doi: 10.1080/08820139.2021.1887888.
doi: 10.1080/08820139.2021.1887888
Perdaens O, Dang HA, D’Auria L, van Pesch V. CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders. Neurol Neuroimmunol Neuroinflamm 2020; 7: doi: 10.1212/NXI.0000000000000673.
doi: 10.1212/NXI.0000000000000673
Zheleznyakova GY, Piket E, Needhamsen M, et al. Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology. Proc Natl Acad Sci U S A 2021; 118: doi: 10.1073/pnas.2011574118.
doi: 10.1073/pnas.2011574118
Santoro M, Nociti V, Lucchini M, et al. Expression profile of long non-coding RNAs in serum of patients with multiple sclerosis. J Mol Neurosci 2016; 59:18–23.
Santoro M, Nociti V, Lucchini M, et al. A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients. Eur Rev Med Pharmacol Sci 2020; 24:3267–3273.
Shaker OG, Mahmoud RH, Abdelaleem OO, et al. LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis. Biosci Rep 2019; 39: doi: 10.1042/BSR20181335.
doi: 10.1042/BSR20181335
Dominguez-Mozo MI, Nieto-Guerrero A, Perez-Perez S, et al. MicroRNAs of human herpesvirus 6A and 6B in serum and cerebrospinal fluid of multiple sclerosis patients. Front Immunol 2020; 11:2142.
Zurawska A, Mycko MP, Selmaj KW. Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis. J Neuroimmunol 2019; 334:576971.
Zurawska AE, Mycko MP, Selmaj I, et al. Multiple sclerosis: circRNA profile defined reveals links to B-cell function. Neurol Neuroimmunol Neuroinflamm 2021; 8: doi: 10.1212/NXI.0000000000001041.
doi: 10.1212/NXI.0000000000001041
Iparraguirre L, Alberro A, Sepulveda L, et al. RNA-Seq profiling of leukocytes reveals a sex-dependent global circular RNA upregulation in multiple sclerosis and 6 candidate biomarkers. Hum Mol Genet 2020; 29:3361–3372.
Han J, Zhuang W, Feng W, et al. The circular RNA circINPP4B acts as a sponge of miR-30a to regulate Th17 cell differentiation during progression of experimental autoimmune encephalomyelitis. Cell Mol Immunol 2021; 18:2177–2187.